Total body-surface area as a new prognostic variable in mycosis fungoides and Sézary syndrome

References

• Song SX, Willemze R, Swerdlow SH, et al. Mycosis fungoides: report of the 2011 Society for Hematopathology/European Association for Hematopathology workshop. Am J Clin Pathol. 2013;139:466–490.
   PubMed Web of Science ®Google Scholar
• Olsen E, Vonderheid E, Pimpinelli N, et al.; ISCL/EORTC revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713–1722.
   PubMed Web of Science ®Google Scholar
• Wilcox RA. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:928–948.
   PubMed Web of Science ®Google Scholar
• Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139:857–866.
   PubMed Web of Science ®Google Scholar
• Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013;49:2859–2868.
   PubMed Web of Science ®Google Scholar
• Vonderheid EC, Pavlov I, Delgado JC, et al. Prognostic factors and risk stratification in early mycosis fungoides. Leuk Lymphoma. 2014;55:44–50.
   PubMed Web of Science ®Google Scholar
• Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730–4739.
   PubMed Web of Science ®Google Scholar
• Vidulich KA, Talpur R, Bassett RL, et al. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol. 2009;48:243–252.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Whittaker S, Kim YH, et al; International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29:2598–2607.
   PubMed Web of Science ®Google Scholar
• Stevens SR, Ke MS, Parry EJ, et al. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT) Arch Dermatol. 2002;138:42–48.
   PubMed Web of Science ®Google Scholar
• Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19: 376–388.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–3115.
   PubMed Web of Science ®Google Scholar
• Williams RY, Wohlgemuth SD. Does the ‘rule of nines’ apply to morbidly obese burn victims? J Burn Care Res. 2013;34:447–452.
   PubMed Web of Science ®Google Scholar
• Parvizi D, Kamolz LP, Giretzlehner M, et al. The potential impact of wrong TBSA estimations on fluid resuscitation in patients suffering from burns: things to keep in mind. Burns. 2014;40:241–245.
   PubMed Web of Science ®Google Scholar
• Langerak AW, Groenen PJ, Brüggemann M, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012;26:2159–2171.
   PubMed Web of Science ®Google Scholar
• Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Statist Med. 2006;25:127–141.
   PubMed Web of Science ®Google Scholar
• Tobisawa S, Honma M, Ishida-Yamamoto A, et al. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor. J Dermatol Sci. 2013;71:160–166.
   PubMed Web of Science ®Google Scholar
• Clark RA, Chong B, Mirchandani N, et al. The vast majority of CLA + T cells are resident in normal skin. J Immunol. 2006;176:4431–4439.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Kim YH, Whittaker SJ, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? Br J Dermatol. 2014;170:1226–1236.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Allgöwer M, Schoenenberger GA, Sparkes BG. Burning the largest immune organ. Burns. 1995;21(Suppl. 1):S7–S47.
   Google Scholar
• Committee on Trauma, American College of Surgeons. Guidelines for the Operation of Burn Centers. In: Resources for optimal care of the injured patient. Chicago, IL: American College of Surgeons; 2006. p. 79–86.
   Google Scholar
• Giretzlehner M, Dirnberger J, Owen R, et al. The determination of total burn surface area: how much difference? Burns. 2013;39:1107–1113.
   PubMed Web of Science ®Google Scholar
• Gankande TU, Wood FM, Edgar DW, et al. A modified Vancouver Scar Scale linked with TBSA (mVSS-TBSA): inter-rater reliability of an innovative burn scar assessment method. Burns. 2013;39:1142–1149.
   PubMed Web of Science ®Google Scholar
• Mahar PD, Wasiak J, Hii B, et al. A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres. Burns. 2014;40:1245–1254.
   PubMed Web of Science ®Google Scholar
• Suga H, Sugaya M, Miyagaki T, et al. Skin barrier dysfunction and low antimicrobial peptide expression in cutaneous T-cell lymphoma. Clin Cancer Res. 2014;20:4339–4348.
   PubMed Web of Science ®Google Scholar